Follow-On Biologic Stakeholders Agree On Patent Resolution, Differ On Details

Inclusion of a mechanism for patent dispute resolution in the pathway for approving follow-on biologics was supported by representatives on both sides of the FOB debate during a Federal Trade Commission workshop Nov. 21